This site uses cookies to store information on your computer. Learn more x

Consensus Figures

A number of international financial analysts cover DSM. The most recent consensus figures – provided by Vara Research – are detailed below. The figures are based on the estimates given by the banks that were approached by Vara Research.

Analysts' consensus Q2 2018 and FY 2018 as at 16 July 2018

  Q2 2017 FY 2017 Q1 2018 Q2 2018 E FY 2018 E
Total Sales          
  Number of Estimates       14 13
  Highest       2,448 9,517
  Consensus 2,161 8,632 2,435 2,367 9,261
  Median       2,361 9,283
  Lowest       2,251 8,928
Total adjusted EBITDA          
  Number of Estimates       14 13
  Highest       514 1,841
  Consensus 376 1,445 538 498 1,811
  Median       501 1,811
  Lowest       467 1,775
of which adj. EBITDA from"Temporary Vitamin Effect"          
  Number of Estimates       10 8
  Highest       110 275
  Consensus - - 165 100 267
  Median       100 270
  Lowest       85 250
           
Total adjusted EBIT          
  Number of Estimates       13 13
  Highest       397 1,367
  Consensus 256 957 423 379 1,325
  Median       382 1,338
  Lowest       344 1,242
Nutrition, Sales          
  Number of Estimates       14 13
  Highest       1,628 6,275
  Consensus 1,380 5,579 1,650 1,558 6,088
  Median       1,568 6,135
  Lowest       1,447 5,738
Nutrition, adj. EBITDA          
  Number of Estimates       14 13
  Highest       407 1,416
  Consensus 271 1,053 442 386 1,386
  Median       386 1,385
  Lowest       357 1,326
of which adj. EBITDA from"Temporary Vitamin Effect"          
  Number of Estimates       10 8
  Highest       110 275
  Consensus - - 165 100 267
  Median       100 270
  Lowest       85 250
Nutrition, adj. EBIT          
  Number of Estimates       13 12
  Highest       335 1,133
  Consensus 198 770 370 313 1,096
  Median       314 1,095
  Lowest       284 1,031
Materials, Sales          
  Number of Estimates       14 13
  Highest       790 3,002
  Consensus 725 2,825 738 752 2,946
  Median       761 2,945
  Lowest       709 2,869
Materials, adj. EBITDA          
  Number of Estimates       14 13
  Highest       142 534
  Consensus 128 488 126 135 521
  Median       136 521
  Lowest       129 499
Materials, adj. EBIT          
  Number of Estimates       13 12
  Highest       111 407
  Consensus 96 361 95 104 395
  Median       104 396
  Lowest       97 379
Innovation Center, Sales          
  Number of Estimates       14 13
  Highest       46 186
  Consensus 41 169 36 41 169
  Median       42 166
  Lowest       36 144
Innovation Center, adj. EBITDA          
  Number of Estimates       14 13
  Highest       6 22
  Consensus 0 9 -1 2 9
  Median       2 9
  Lowest       -1 -1
Innovation Center, adj. EBIT          
  Number of Estimates       13 12
  Highest       1 -8
  Consensus -7 -30 -6 -4 -17
  Median       -5 -18
  Lowest       -8 -29
Corporate Activities, Sales          
  Number of Estimates       14 13
  Highest       22 77
  Consensus 15 59 11 16 58
  Median       15 59
  Lowest       11 49
Corporate Activities, adj. EBITDA          
  Number of Estimates       14 13
  Highest       -22 -95
  Consensus -23 -105 -29 -25 -105
  Median       -25 -105
  Lowest       -29 -110
Corporate Activities, adj. EBIT          
  Number of Estimates       13 12
  Highest       -32 -134
  Consensus -31 -144 -36 -34 -141
  Median       -33 -142
  Lowest       -39 -149
Profit for the period, before exceptional items - Cont. Ops.          
  Number of Estimates       13 14
  Highest       483.0 1,125.0
  Consensus 175.0 706.0 337.0 307.0 1,035.0
  Median       289.0 1,032.0
  Lowest       262.0 903.0
Net EPS before exceptional items - Cont. Ops.          
  Number of Estimates       13 14
  Highest       1.81 6.44
  Consensus 0.98 3.92 1.91 1.67 5.87
  Median       1.65 5.84
  Lowest       1.49 5.16

Disclaimer
Consensus earnings estimates are based on earnings projections made by securities analysts who cover DSM. Any opinions, forecasts, estimates, projections or predictions regarding DSM’s performance made by the analysts (and, therefore, the Consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of DSM or its management. DSM does not by providing these estimates imply its endorsement of or concurrence with such information, conclusions or recommendations. DSM assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.